Mainstays Give And Take As Major Japan Firms Report Results

Xtandi Pressures, Enhertu Prospects

While Daiichi Sankyo reveals ambitious plan with Enhertu, Chugai shows stable growth plans with COVID-19 drugs, Astellas reacted to concerns over Xtandi’s slow growth with enthusiastic investment plan for the next potential star.

Financial Report Released by Astellas, Chugai, Daiichi Snakyo
Astellas, Chugai, Daiichi Sankyo Has Shown Key Strategies For 2022 • Source: Shutterstock

Continued growth of mainstay products and favorable currency tailwinds emerged as common themes as major players in Japan’s pharmaceutical industry released fiscal year and first quarter results and outlined key strategic plans for the rest of the year.

While Daiichi Sankyo Co., Ltd. revealed ambitious plans for its rapidly rising oncology star Enhertu, Chugai Pharmaceutical Co.,...

More from Japan

More from Focus On Asia